TMS and Exercise for Post-stroke Pain

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Recruiting
CT.gov ID
NCT04672044
Collaborator
(none)
32
1
2
17.5
1.8

Study Details

Study Description

Brief Summary

There are over 7 million people living with stroke in the United States. Per year, approximately 17,000 Veterans are admitted to the VA for acute stroke. Chronic pain after stroke can occur between 10-50% of stroke survivors. Post-stroke pain (PSP) can lead to further complications in a stroke survivor's recovery. Exercise has improved PSP and associated symptoms such as mobility, fatigue, and quality of life. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive technique using electromagnetic induction for cortical neurostimulation. The use of rTMS has been explored shown to be effective in treating chronic PSP but is limited in effect duration. Our proposal will test the hypothesis that rTMS is feasible and safe to be paired with exercise. Additionally, the investigators believe a complementary effect can develop to enhance the neurostimulation duration of rTMS.

Condition or Disease Intervention/Treatment Phase
  • Device: Active rTMS and exercise
  • Combination Product: Sham rTMS+Exercise
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Feasibility of a double-blind sham-controlled interventionFeasibility of a double-blind sham-controlled intervention
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double-blind
Primary Purpose:
Treatment
Official Title:
Feasibility of Combination Exercise and Neuromodulation Rehabilitation to Improve Post-stroke Chronic Pain
Actual Study Start Date :
Jan 14, 2022
Anticipated Primary Completion Date :
Jun 29, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: active rTMS+Exercise

active rTMS

Device: Active rTMS and exercise
active

Sham Comparator: sham rTMS+Exercise

sham rTMS

Combination Product: Sham rTMS+Exercise
sham

Outcome Measures

Primary Outcome Measures

  1. Visual Analogue Scale for Pain [through study completion, an average of 12 weeks]

    The visual analog scale (VAS) is a validated, subjective measure for pain. Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm)

Other Outcome Measures

  1. modified Rankin Scale [through study completion, an average of 12 weeks]

    Measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Score Description: 0 No symptoms at all No significant disability despite symptoms; able to carry out all usual duties and activities Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Moderate disability; requiring some help, but able to walk without assistance Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention Dead

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female Veteran of US military 19 years of age

  • Signed informed consent

  • Minimum of 3-months since time of stroke and medically stable

  • Headache has persisted for >3 months after stabilization of the stroke

  • Ability to walk or tolerate recumbent cycle ergometry for 10 mins without assistance

  • Stable pain medication regimen for 1 month prior to study

  • Females of child-bearing potential (i.e. not postmenopausal or surgically sterile) must be using a medically acceptable method of birth control and should not be pregnant nor have plans for pregnancy or breastfeeding during the study

  • Completed diagnostic, maximal graded exercise test including 12-lead ECG and indirect calorimetry (i.e. oxygen uptake, minute ventilation, respiratory exchange ratio, etc.)

  • Minimum pain intensity of 30 on the Mechanical Visual Analogue Scale on average with pain symptoms.

Exclusion Criteria:
  • Moderate to severe cognitive impairment (Montreal Cognitive Assessment score <16/30)

  • Pre-stroke modified Rankin >2

  • History of seizures

  • Presence of any standard TMS or MRI contraindications (see human subjects)

  • Current diagnosis of DSM-5-defined bipolar disorder I, schizophrenia, schizoaffective disorder, or obsessive-compulsive disorder

  • Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 3 months (Participants must agree to abstain from illicit drugs during the study)

  • Increased risk of suicide that necessitates inpatient treatment or warrants additional therapy excluded by the protocol; and/or intensity of suicidal ideation (Type 4 or Type 5) or any suicidal behavior in the past 3 months on Columbia Suicide Severity Rating Scale (C-SSRS)

  • Litigating for compensation for a psychiatric disorder

  • Veterans who are in the process of applying for or receiving VA service-connected disability are eligible

  • Current enrollment in another intervention trial for pain or stroke

  • Persons imprisoned, of minor age, diagnosed with terminal illness, or require surrogate for consent

  • Fails baseline exercise screening activities

  • Persistent post-stroke headaches not better accounted for by another diagnosis

  • Is unable to reliably attend intervention sessions i.e. planning to move, transportation issues

  • Neurological disorder pre- or post- stroke affecting subject's ability to follow study directions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Birmingham VA Medical Center, Birmingham, AL Birmingham Alabama United States 35233

Sponsors and Collaborators

  • VA Office of Research and Development

Investigators

  • Principal Investigator: Chen Lin, MD, Birmingham VA Medical Center, Birmingham, AL

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT04672044
Other Study ID Numbers:
  • B3612-P
  • I21RX003612
First Posted:
Dec 17, 2020
Last Update Posted:
Feb 2, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 2, 2022